Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DOD Biotech PCLBKK:DOD-R -5.84%67 3-Year Revenue Growth Rate is 1.10% as of Jun. 2026, which is 89% below its 10-year median of 10.20. GuruFocus rates BKK:DOD-R with a GF Score™ of 67/100 and a GF Value™ of ฿1.52. The stock has 6 warning signs investors should review. Among 1,846 Consumer Packaged Goods companies, DOD Biotech PCL ranks worse than 60.46% on this metric.
During the past 12 months, DOD Biotech PCL's average Revenue per Share Growth Rate was -18.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 1.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -12.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of DOD Biotech PCL was 463.40% per year. The lowest was -16.60% per year. And the median was 10.20% per year.
DOD Biotech PCL (BKK:DOD-R) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
DOD Biotech PCL 3-Year Revenue Growth Rate Related Terms
BKK:DOD-R vs KHC, GIS: 3-Year Revenue Growth Rate Comparison
For the Packaged Foods subindustry, DOD Biotech PCL's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DOD Biotech PCL 3-Year Revenue Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where DOD Biotech PCL's 3-Year Revenue Growth Rate falls into.
DOD Biotech PCL 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 1.10% mean?
DOD Biotech PCL (BKK:DOD-R) has a 3-Year Revenue Growth Rate of 1.10% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for DOD Biotech PCL and its competitors. This is 89% below median its historical median of 10.20. According to the industry distribution chart, DOD Biotech PCL ranks #1116 out of 1846 companies in the Consumer Packaged Goods industry, placing it in the top 60.5%.
Is DOD Biotech PCL's 3-Year Revenue Growth Rate too high?
DOD Biotech PCL's current 3-Year Revenue Growth Rate of 1.10% is 89% below median its 10-year median of 10.20. The Consumer Packaged Goods industry median 3-Year Revenue Growth Rate is 3.50. DOD Biotech PCL's value of 1.10% is 68.6% below this industry median. Based on the distribution chart, DOD Biotech PCL ranks #1116 out of 1846 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's 3-Year Revenue Growth Rate compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, DOD Biotech PCL ranks #1116 out of 1846 companies for 3-Year Revenue Growth Rate. This places DOD Biotech PCL in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 3.50. DOD Biotech PCL's value of 1.10% is 68.6% below this benchmark. While the company's 10-year median is 10.20 vs. the industry median of 3.50, DOD Biotech PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Consumer Packaged Goods company?
The median 3-Year Revenue Growth Rate among Consumer Packaged Goods companies is 3.50, based on 1,846 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DOD Biotech PCL's current 3-Year Revenue Growth Rate of 1.10% is 68.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for DOD Biotech PCL and its competitors. For the Consumer Packaged Goods industry, the median 3-Year Revenue Growth Rate is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DOD Biotech PCL's current 3-Year Revenue Growth Rate is 1.10%, which is 89% below median its own 10-year median of 10.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current 3-Year Revenue Growth Rate of 1.10%. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current 3-Year Revenue Growth Rate is 1.10%, which is 89% below median its 10-year median of 10.20 and 68.6% below the Consumer Packaged Goods industry median of 3.50. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current 3-Year Revenue Growth Rate is 1.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?
Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued.
The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.
Key valuation signals for BKK:DOD-R:
3-Year Revenue Growth Rate: 1.10% (89% below median its 10-year median of 10.20)
GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
Industry Position: 68.6% below the Consumer Packaged Goods median (#1116 of 1846)
No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score
Get the complete analysis for BKK:DOD-R
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:DOD-R has been successfully added to your 
